Naslov
Local estrogen treatment in patients with urogenital symptoms

Autori
Šimunić, Velimir ; Banović, Ivo ; Ciglar, Srećko ; Jeren, Lana, Pavičić Baldani, Dinka ; Šprem, Marina

Izvornik
International journal of gynaecology and obstetrics (0020-7292) 82 (2003); 187-197

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
local estrogen treatment ; efficacy ; safety ; urogenital symptoms

Sažetak
Objective was to determine the efficacy and safety of low dose (25  g) micronized 17  -estradiol administered vaginally in the management of patients with urogenital symptoms. A total of 1612 patients with urogenital complaints were randomized to receive 25  g of micronized 17 -estradiol (828) or placebo (784) in a multicentric double-blind placebo controlled study running for 12 months. The women were treated once a day for two weeks, and then twice a week for the rest of the twelve months with the active or placebo tablet. The assessment included full history-questionnaire, micturition diary, gynecological and cystometric examination, transvaginal ultrasound and serum estradiol level determination. It was carried out at the beginning, and after four and twelve months of treatment. The overall success rate of micronized 17 -estradiol on subjective and objective symptoms of postmenopausal women with vaginal atrophy was 85.5%, and the effect of placebo was 41.4%. A significant improvement of urinary atrophy symptoms was determined in vaginal ERT group comparing with the beginning of the study (51.9% vs. 15.5%, p=0.001). Maximal cystometric capacity and the volume of the urinary bladder at which patients first felt urgency and strong desire to void were considerably larger after micronized 17 -estradiol treatment than before it. The number of patients with uninhibited bladder contractions significantly decreased after micronized 17 -estradiol compared with the values before the treatment or after placebo. Side effects were observed in 61 (7.8%) patients treated with low dose micronized 17- estradiol. We found that 25  g of micronized 17- estradiol do not raise serum estrogen level and do not stimulate endometrial growth. Local administration of 25  g of micronized 17- estradiol is effective and safe treatment option in the management of women with urogenital complaints.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA